Benzinga - by Avi Kapoor, Benzinga Staff Writer.
Although U.S. stocks closed little changed on Monday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
Semtech
- The Trade: Semtech Corporation (NASDAQ: SMTC) EVP and CFO Mark Lin acquired a total of 1,000 shares an average price of $33.23. To acquire these shares, it cost around $33,232.
- What’s Happening: On March 28, Semtech posted a loss for the fourth quarter.
- What Semtech Does: Semtech Corp is engaged in designing, developing, manufacturing and marketing analog and mixed-signal semiconductors, algorithms and wireless semiconductors, connectivity modules, gateways, routers and connected services for IoT.
- The Trade: Greif, Inc. (NYSE: GEF) Executive VP & General Counsel Gary R Martz acquired a total of 10,082 shares at an average price of $68.23. To acquire these shares, it cost around $687,932.
- What’s Happening: On Feb. 28, Greif posted upbeat quarterly earnings.
- What Greif Does: Greif Inc is a producer of industrial packaging products and services with manufacturing facilities located in many countries.
Zumiez
- The Trade: Zumiez Inc. (NASDAQ: ZUMZ) President International Adam Christopher Ellis bought a total of 10,000 shares at an average price of $14.31. To acquire these shares, it cost around $143,100.
- What’s Happening: On March 20, B. Riley Securities analyst Jeff Van Sinderen maintained Zumiez with a Neutral and lowered the price target from $19 to $16.
- What Zumiez Does: Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods.
- The Trade: AngioDynamics, Inc. (NASDAQ: ANGO) President and CEO James C Clemmer bought a total of 10,000 shares at an average price of $6.70. The insider spent around $67,000 to buy those shares.
- What’s Happening: On April 4, AngioDynamics received FDA 510(k) clearance For AlphaVac F1885 System For Pulmonary Embolism.
- What AngioDynamics Does: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
Check This Out: Investor Optimism Improves; Fear & Greed Index Remains In 'Greed' Zone
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.